5 • 644 Ratings
🗓️ 8 August 2023
⏱️ 42 minutes
🧾️ Download transcript
In this episode, we announce the second iteration of the HelixTalk Drug Superlative Awards -- awards given to medications on the market that are outstanding or notorious. In announcing these completely fictitious awards, we review key clinical pearls and pitfalls that every clinician should be aware of with these notable medications.
Key Concepts
References
Click on a timestamp to play from that location
0:00.0 | Welcome to Helix Talk, an educational podcast for healthcare students and providers covering real-life clinical pearls, professional pharmacy topics, and drug therapy discussions. |
0:11.0 | This podcast is provided by pharmacists and faculty members at Rosal Franklin University College of Pharmacy. |
0:17.0 | This podcast contains general information for educational purposes only. This is not professional |
0:22.4 | advice and should not be used in lieu of obtaining advice from a qualified health care provider. |
0:27.2 | And now on to the show. Welcome to Helix Talk episode 169. I'm your co-host Dr. Kane. And I'm |
0:36.4 | Dr. Patel. And I'm Dr. Patel. |
0:41.9 | And I'm proud to announce today's episode entitled Introducing Helix Talks 2023 Drug Superlative Awards. |
0:45.4 | So for the listeners that recall way back to episode 128 in March of 2021, we actually had |
0:51.5 | the debut of the Helix Talk drug superlative awards. |
0:55.1 | These are awards that are kind of given because of a notable thing about a drug or a drug |
1:00.0 | class, and we decided it was about time to have a new round of those awards. |
1:05.8 | Dr. Kane, this is my favorite episode because, A, you know, they're hilarious, and B, we're learning something new. |
1:13.3 | I am learning something new, too. |
1:15.1 | So I know back in March, we talked about, you know, things like drugs that is most likely to remember for COVID-19 ineffectiveness rather than its FDA indication, aka hydroxychloroquine. |
1:29.8 | We were talking about commonly used, but the worst anti-hypretensives that are in the market, |
1:34.7 | like the atanol and hydrochlorothyazide. |
1:37.6 | And then we also covered the most confusing dosage form, which was valproac acid or divalprox |
1:42.6 | or valporeate sodium, all all three the same thing we also covered |
1:46.6 | the most innovative pro drug which was val acyclevere and then finally the hottest inactive |
1:52.1 | ingredient which was actually a tie for sulfobutal beta cyclodextrin or sbectrine or sbecd the |
1:58.6 | excipient in remdesivir and also tie for polyethylene glycol or peg, |
2:04.1 | which was one of the recipients in the MRNA vaccines for COVID-19. |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Sean P. Kane, PharmD, BCPS, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Sean P. Kane, PharmD, BCPS and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.